本文選題：首發(fā)精神分裂癥 + 膠質(zhì)纖維酸性蛋白��； 參考：《昆明醫(yī)科大學(xué)》2013年碩士論文

【摘要】：目的探討首發(fā)精神分裂癥患者血清膠質(zhì)纖維酸性蛋白(GFAP)濃度及其基因SNPrs2070935多態(tài)性與疾病的關(guān)聯(lián) 方法我們對門診收集的58例首發(fā)精神分裂癥的患者,及來自健康體檢的52例年齡、性別匹配的正常對照進(jìn)行研究。完成自制一般情況調(diào)查問卷及PANSS以評估病情程度。采用酶聯(lián)免疫吸附劑法(enzyme linked immunosorbent assay, ELISA)測定血清GFAP濃度,采用聚合酶鏈?zhǔn)椒磻?yīng)(Polymerase Chain Reaction, PCR)擴(kuò)增目的片段,測定PCR產(chǎn)物的DNA序列,進(jìn)行序列比對后判定GFAP基因SNPrs2070935基因型。采用t檢驗(yàn)、χ2檢驗(yàn)、方差分析及Spearman相關(guān)分析進(jìn)行數(shù)據(jù)統(tǒng)計(jì)分析。 結(jié)果(1)首發(fā)精神分裂癥患者血清GFAP濃度高于對照組(4.21±0.72ng/Lvs3.33±0.85ng/L, t=5.90, P0.01),分別與不同性別、年齡、]PANSS得分等因素進(jìn)行分析,結(jié)果顯示血清GFAP濃度與在這些因素中的差異無統(tǒng)計(jì)學(xué)意義；(2)總樣本三種基因型的構(gòu)成比：CC型(56.36%)、CA型(34.55%)、AA型(9.09%)；病例組構(gòu)成比分別為44.83%、41.38%、13.79%；對照組為69.23%、26.92%、3.85%,病例組與對照組間基因型的分布具有統(tǒng)計(jì)學(xué)差異(χ2=7.54,P=0.023),同時(shí)等位基因頻率分布也具有統(tǒng)計(jì)學(xué)差異(χ2=8.33,P=0.004)；.(3)三種基因型的血清GFAP濃度無統(tǒng)計(jì)學(xué)差異(F=0.85,P=0.43),病例組與對照組不同基因型的血清GFAP濃度也無統(tǒng)計(jì)學(xué)差異(F值分別為0.73和0.07,P值分別為0.69和0.94)。 結(jié)論病例組的血清GFAP濃度高于對照組,而GFAP基因多態(tài)性與血清GFAP濃度無相關(guān)性,表明首發(fā)精神分裂癥患者存在神經(jīng)膠質(zhì)細(xì)胞損害,推測是在反饋性保護(hù)機(jī)制下,GFAP參與了神經(jīng)膠質(zhì)細(xì)胞損傷后的修復(fù)與再生。而血清GFAP濃度改變與基因突變無關(guān),可能與其他多種因素的參與有關(guān)；另研究結(jié)果顯示人群GFAP基因的突變與精神分裂癥發(fā)病存在一定的關(guān)聯(lián),表明這一突變基因在精神分裂癥的發(fā)病中可能是一個(gè)潛在的危險(xiǎn)因子。
[Abstract]:Objective to investigate the association between serum glial fibrillary acidic protein (GFAP) concentration, gene SNPrs2070935 polymorphism and disease in patients with first-episode schizophrenia. Methods We studied 58 first-episode schizophrenia patients and 52 age-matched healthy controls. Self-made general situation questionnaire and PANSS were completed to assess the severity of the disease. Enzyme linked immunosorbent assay (Elisa) was used to detect the concentration of GFAP in serum, and polymerase chain reaction (PCR) was used to amplify the DNA sequence of PCR product. The SNPrs2070935 genotype of GFAP gene was identified after sequence alignment. T test, 蠂 2 test, ANOVA and Spearman correlation analysis were used to analyze the data. Results (1) the serum GFAP concentration in the first episode schizophrenic patients was higher than that in the control group (4.21 鹵0.85ng / L, t = 5.90, P 0.01g / L, respectively). The results were analyzed with sex, age,] PANSS score and so on. The results showed that there was no significant difference between the serum GFAP concentration and these factors. (2) the composition of the three genotypes in the total sample was higher than that in the total sample: the composition of the three genotypes in the total sample was higher than that in the control group (69.23%, 26.922%, 3.85%, in the control group, 69.23%, 26.922%, 3.85%, in the control group, and in the control group, respectively, the ratio was 44.8333.38 13.79). There was no statistical difference in the distribution of serum GFAP among the three genotypes (蠂 ~ 2 ~ (7.54) (蠂 ~ (2) = 7.54) and allele frequency (蠂 ~ (2) = 8.33). There was no significant difference in serum GFAP concentration among the three genotypes. The serum GFAP concentration of different genotypes in the case group and the control group was no significant difference, and there was no significant difference in the serum GFAP concentration between the patients and the control group. The F values were 0.73 and 0.07, P values were 0.69 and 0.94 respectively. Conclusion the concentration of serum GFAP in the case group is higher than that in the control group, but there is no correlation between the GFAP gene polymorphism and the serum GFAP concentration, which indicates that there is glial cell damage in the patients with first-episode schizophrenia. It is speculated that GFAP is involved in the repair and regeneration of glial cells after injury under the feedback protection mechanism. However, the change of serum GFAP concentration is not related to gene mutation, but may be related to many other factors. The results also show that the mutation of GFAP gene is associated with the onset of schizophrenia. These results suggest that this mutation gene may be a potential risk factor in the pathogenesis of schizophrenia.
【學(xué)位授予單位】：昆明醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2013
【分類號】：R749.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前8條

1 徐波,汪德文,趙忠凱,吳旭,陳懷芳,張國華,李如波,袁翔天;用GFAP和VIM表達(dá)推斷腦損傷時(shí)間的實(shí)驗(yàn)研究[J];中國法醫(yī)學(xué)雜志;2000年01期

2 陶陸陽,汪德文,劉子和,曹明,趙榮輝,吳旭,姜彥多;人腦挫傷后S-100和GFAP的變化[J];中國法醫(yī)學(xué)雜志;2000年02期

3 周云飛,趙靖平;精神分裂癥認(rèn)知功能損害與病程的關(guān)系[J];臨床精神醫(yī)學(xué)雜志;2001年04期

4 邵林華;陳亦華;鄭龍;程振宇;俞建華;;顱腦損傷患者血清GFAP含量變化及其臨床意義[J];全科醫(yī)學(xué)臨床與教育;2011年03期

5 李東陽;周秀芳;孫曉東;陳濤;魯娜;;柴胡龍牡湯對精神分裂癥大鼠模型刻板行為和膠質(zhì)細(xì)胞纖維酸性蛋白(GFAP)表達(dá)的影響[J];現(xiàn)代預(yù)防醫(yī)學(xué);2011年07期

6 李元,肖紅,高曉寧,李永平;首發(fā)精神分裂癥患者血液中神經(jīng)元特異性烯醇化酶和髓鞘堿性蛋白的改變[J];中華精神科雜志;2004年03期

7 林淑香;;穩(wěn)定期精神分裂癥認(rèn)知功能及相關(guān)因素[J];中國民康醫(yī)學(xué);2010年05期

8 李淑英,呂路線,趙幸福,郭慧榮,趙崢,高福蓮;精神分裂癥患者腦脊液中神經(jīng)元特異性烯醇化酶和髓鞘堿性蛋白的研究[J];中國神經(jīng)精神疾病雜志;2002年04期

，

本文編號：1947357